Jeffrey Pealrman, 49, of Edgewood, N.J., allegedly orchestrated a scheme that paid registered nurses and physicians' assistants in Connecticut, New York, New Jersey and Rhode Island to prescribe his company's fentanyl-based, pain-relief medication to cancer patients, according to the U.S. attorneys office.